Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Up to 50% of patients with chronic obstructive pulmonary disease (COPD) in stable state
may carry potentially pathogenic microorganisms (PPMs) in their airways. The presence of …

Chronic obstructive pulmonary disease (COPD) is partly characterized as epithelial–
mesenchymal transition (EMT)-related airflow limitation. Extracellular vesicles (EVs) play …

Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-
acting β2-agonists (LABAs) in combination is currently the mainstay of treatment for chronic …

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality
around the world. COPD is characterised by a heterogeneous clinical presentation and …

Background Persistent airflow limitation and dyspnoea may reduce chronic obstructive
pulmonary disease (COPD) patients exercise capacity and physical activity, undermining …

Chronic pharyngitis is a common disease, which has a long duration and a wide range of
onset. It is easy to misdiagnose by mistaking it with other diseases, such as chronic …

Chronic obstructive pulmonary disease (COPD) is heterogeneous, but persistent airflow
obstruction (AFO) is fundamental to diagnosis. We studied AFO consistency from initial …

Objective To assess the incidence and determinants of the triple inhaled therapy in chronic
obstructive pulmonary disease (COPD) primary care patients. Methods Data derived from …

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and
mortality worldwide. While the cut-off point to define airflow obstruction has been …